Johnson & Johnson, AbbVie shore up Imbruvica's CLL lead with Gazyva combo win

28th January 2019 Uncategorised 0

Add another indication for Imbruvica in chronic lymphocytic leukemia to the list. On Monday, partners AbbVie and Johnson & Johnson said the standout drug had picked up another FDA green light in the disease, this time in combination with Roche’s Gazyva.

More: Johnson & Johnson, AbbVie shore up Imbruvica's CLL lead with Gazyva combo win
Source: fierce